New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs Cerebrolysin

Livagen vs Cerebrolysin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
Cognitive EnhancementAnti-Aging & Longevity
Cerebrolysin
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
Half-Life
Short (minutes); gene-regulatory effects are sustained
Variable for the complex; individual peptide fractions: minutes to hours
Admin Route
SubQ, Oral
IV, IM
Research
Typical Dose
10 mg per day
5–10 mL
Frequency
Daily for 10–30 days
Daily for 10–20 days
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Promotes neurogenesis and synaptic plasticity
  • Approved for stroke rehabilitation (accelerates recovery)
  • Alzheimer's disease: slows progression and improves cognition
  • Traumatic brain injury recovery
  • Enhances memory and executive function
  • Neuroprotection against oxidative stress and excitotoxicity
  • Anti-amyloid and anti-tau effects
  • Mood improvement and reduced anxiety
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Generally well tolerated
  • Mild nausea and dizziness (IV infusion)
  • Headache at initiation
  • Rare: agitation (usually at very high doses)
  • +2 more
Stacks With